Drug Trial Radar · NCT06768489
A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Dec 4, 2024
Primary completion
Jan 2, 2029
Study completion Jun 29, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for ramantamig treatment regimens and JNJ-102299639 treatment regimens; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of ramantamig and JNJ-102299639 treatment regimens at selected RP2D(s).
Conditions
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Immunoglobulin Light-chain Amyloidosis
Interventions
RamantamigDrug
Ramantamig will be administered subcutaneously.
DaratumumabDrug
Daratumumab will be administered subcutaneously.
PomalidomideDrug
Pomalidomide will be administered orally.
LenalidomideDrug
Lenalidomide will be administered orally.
JNJ-102299639Drug
JNJ-102299639 will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Up to 28 days
- Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 3 Years and 3 months
- Number of Participants with Clinically Significant Laboratory AbnormalitiesTime frame: Up to 3 Years and 3 months
Locations
16 sites in 5 countries. Site status is shown where the registry gives one.
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Winship Cancer Institute Emory University
Atlanta, Georgia · Recruiting
Monash Medical Centre
Clayton, Australia · Recruiting
St Vincents Hospital Melbourne
Fitzroy, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
Calvary Mater Newcastle Hospital
Waratah, Australia · Recruiting
Wollongong Hospital
Wollongong, Australia · Recruiting
Carmel Medical Center
Haifa, Israel · Recruiting
Sheba Medical Center
Ramat Gan, Israel · Recruiting
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel · Recruiting
Hadassah Medical Center
Yeruham, Israel · Recruiting
VU Medisch Centrum
Amsterdam, Netherlands · Recruiting
Universitair Medisch Centrum Groningen
Groningen, Netherlands · Recruiting
UMC Utrecht
Utrecht, Netherlands · Recruiting
Hosp. Clinic de Barcelona
Barcelona, Spain · Recruiting
Hosp Clinico Univ de Salamanca
Salamanca, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.